Scientists at the Swiss Federal Institute of Technology, in collaboration with the Institute for Systems Biology in Seattle, Washington, USA, have created assays for approximately 20?000 human proteins, generating what is claimed to be the world?s first human Multiple Reaction Monitoring Atlas.
Scientists at the Swiss Federal Institute of Technology (ETH Zurich), in collaboration with the Institute for Systems Biology in Seattle, Washington, USA, have created assays for approximately 20 000 human proteins, generating what is claimed to be the world’s first human Multiple Reaction Monitoring (MRM) Atlas. Scientists around the world will be able to use this atlas to significantly advance biomarker research, protein-based drug development and fundamental biological and biomedical research.
The project used Agilent’s triple quadrupole and quadrupole time-of-flight LC–MS systems, nanoflow HPLC-Chip–MS systems and protein analysis software. “In recent years, we’ve devoted a great deal of effort to developing highly sensitive and selective proteomics tools for research,” said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. “We’re delighted to see them being used to such great effect for this vital work.”
The development of the atlas was also dependent on AB SCIEX QTRAP technology, which combines the quantitative MRM capabilities of normal triple quadrupole systems with advanced linear ion trap capabilities for protein identification and confirmation in a single analysis.
Ruedi Aebersold, PhD, Professor, Institute of Biotechnology at the Swiss Federal Institute of Technology stated, “This accomplishment by a dedicated group of scientists is an important milestone and will improve our understanding of the analysis of the human proteome. We could not have developed the MRMAtlas as quickly and productively without QTRAP technology.”
The data will be made accessible to the research community through the ISB/ETH SRMAtlas database (www.srmatlas.org) as part of theISB/ETH PeptideAtlas (www.peptideatlas.org) project.
This story originally appeared in The Column. Click here to view that issue.
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.